Positive results from Phase iib benralizumab study in severe asthma published in the Lancet Respiratory Medicine
10 October 2014 | By AstraZeneca
AstraZeneca announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell...